.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

PD Dr. med. Tobias Ruck

Düsseldorf / DE

Universitätsklinikum

Chair

23/03/2023
12:45 – 13:45
Wissenschaftliche Sitzung
Entzündliche Muskelerkrankungen interdisziplinär
Hörsaal B

Industrieredner

23/03/2023
12:10 – 12:30 15 Min. 5 Min.
Vortrag Industrie
Neurologische Klinik und Poliklinik des Universitätsklinikums
23/03/2023
14:40 – 15:00 15 Min. 5 Min.
Führt die aktualisierte MG-Leitlinie zu einem veränderten Therapieregime? – eine aktuelle Übersicht

eingeladener Redner

23/03/2023
13:25 – 13:35 10 Min. 0 Min.
Vortrag
Die wichtigsten Neuerungen der Myositis-Leitlinie

Further involvements

22/03/2023
Poster
P 86
Beyond complement - proteometabolomics identify the versatile consequences of eculizumab treatment in myasthenia gravis
Pathophysiologie und molekulare Mechanismen, Therapie
22/03/2023
Poster
P 53
Cellular senescence is a prominent feature of inclusion body myositis
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
22/03/2023
Poster
P 56
A simplified murine model of experimental autoimmune myasthenia gravis (EAMG)
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
22/03/2023
Poster
P 4
Periostin level in sporadic inclusion body myositis: a study of blood and muscle
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
22/03/2023
Poster
P 75
Establishment and characterization of a mouse model for anti-synthetase syndrome
Pathophysiologie und molekulare Mechanismen, Varia
22/03/2023
Poster
P 22
A case of triple-A syndrome associated with a novel pathogenic AAAS variant
Case reports
22/03/2023
Poster
P 104
An Open-Label Study to Assess the Clinical Efficacy and Safety of Efgartigimod to Further Individualize Treatment in Patients With Generalized Myasthenia Gravis
Therapie, Varia
23/03/2023
13:35 – 13:45 10 Min. 0 Min.
Freier Vortrag
FV 7
Skeletal muscle expression of immune regulating proteins in myositis subtypes
Pathophysiologie und molekulare Mechanismen, Varia
23/03/2023
15:25 – 15:30 4 Min. 1 Min.
Orales Poster
P 4
Periostin level in sporadic inclusion body myositis: a study of blood and muscle
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
24/03/2023
15:35 – 15:40 4 Min. 1 Min.
Orales Poster
P 56
A simplified murine model of experimental autoimmune myasthenia gravis (EAMG)
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen
24/03/2023
16:10 – 16:15 4 Min. 1 Min.
Orales Poster
P 86
Beyond complement - proteometabolomics identify the versatile consequences of eculizumab treatment in myasthenia gravis
Pathophysiologie und molekulare Mechanismen, Therapie
24/03/2023
17:30 – 17:40 10 Min. 0 Min.
Freier Vortrag
FV 28
Proteomic profiling identifies ITIH3 as biomarker for disease activity in myasthenia gravis
Biomarker - molekular, klinisch, digital, Pathophysiologie und molekulare Mechanismen